Optimization of <i>RAS/BRAF</i> Mutational Analysis Confirms Improvement in Patient Selection for Clinical Benefit to Anti-EGFR Treatment in Metastatic Colorectal CancerCristina Santos, Ramón Salazar, Daniel Azuara et al.|Molecular Cancer Therapeutics|2017Cited by 22
Effect of pharmacogenetic-based selection of first-line chemotherapy on response rate and R0 surgery in metastatic CRC patients.Albert Abad, Eva Martinez‐Balibrea, Enrique Aranda et al.|Journal of Clinical Oncology|2016Cited by 2
Comparison of three molecular methods to detect mutations in <i>KRAS</i>, <i>NRAS</i>, <i>BRAF</i> and <i>PIK3CA</i> in metastatic colorectal cancer (mCRC).Cristina Santos, Ramón Salazar, Rocio García‐Carbonero et al.|Journal of Clinical Oncology|2016Cited by 1
Table S3 from Optimization of <i>RAS/BRAF</i> Mutational Analysis Confirms Improvement in Patient Selection for Clinical Benefit to Anti-EGFR Treatment in Metastatic Colorectal CancerCristina Santos, Ramón Salazar, Daniel Azuara et al.|Unknown|2023Cited by 0
Table S5 from Optimization of <i>RAS/BRAF</i> Mutational Analysis Confirms Improvement in Patient Selection for Clinical Benefit to Anti-EGFR Treatment in Metastatic Colorectal CancerCristina Santos, Ramón Salazar, Daniel Azuara et al.|Unknown|2023Cited by 0